Correlation of c-MYC, BCL2 and BCL6 proteins overexpression with prognosis in Syrian DLBCL Patients
| Autor: | Sulaf Ahmad Farhat Maghrabi, Fawza Mohammad Sharif Monem |
|---|---|
| Jazyk: | Arabic<br />English |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | مجلة جامعة دمشق للعلوم الطبية, Vol 40, Iss 3 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2072-2265 2789-6889 |
| Popis: | Background and Aim: c-MYC is a potent transcription factor involved in several cellular processes, and is overexpressed in many cancers, including non-Hodgkin lymphoma (NHL). The most common subtype of NHL is diffuse large B-cell lymphoma (DLBCL). DLBCL tumors expressing both the c-MYC and BCL2 proteins, i.e. double expressor (DE), also triple expressors (TE) expressing BCL6 in addition to c-MYC and BCL2, are all more aggressive and refractory to treatment. Our study aims to investigate auxiliary immunohistochemical tests (IHC) not routinely used, namely c-MYC, BCL2 and BCL6, seeking a better prognostic testing protocol for DLBCL patients. Materials and Methods: Forty-one formalin-fixed paraffin-embedded (FFPE) DLBCL samples were collected retrospectively from the pathology laboratory at Al-Assad University Hospital after approval from the ethics committee at Damascus University. Clinical data was obtained from patients records in regards to progression-free survival (PFS) and other parameters. Slides were microtomed from each FFPE sample and used to perform IHC tests of the c-MYC, BCL2 and BCL6 oncoproteins. Fisher’s exact test was used to study the independence of protein IHC results in relation to one another and compared with PFS. Results: Statistical analysis of the c-MYC overexpression and double expressor status showed no correlation (P>0.05) with PFS in DLBCL patients. Whereas, when BCL6 IHC results were analyzed, BCL6 positivity and triple expressor status showed a significant association (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|